FDA advisors give PMR (percutaneous myocardial revascularisation) the thumbs down
This article was originally published in Clinica
Executive Summary
An FDA advisory panel has recommended that the agency does not approve CardioGenesis' application to bring the first percutaneous myocardial revascularisation (PMR) system to market in the US.